Multigene assays for classification, prognosis, and prediction in breast cancer: A critical review on the background and clinical utility

Geburtshilfe und Frauenheilkunde

Volumn 73, Issue 9, 2013, Pages 932-940

  Sinn, P ^a   Aulmann, S ^a   Wirtz, R ^b   Schott, S ^a   Marme F ^a   Varga, Z ^c   Lebeau, A ^d   Kreipe, H ^e   Schneeweiss, A ^f  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b STRATIFYER Molecular Pathology GmbH   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f National Center of Tumor Diseases   (Germany)

Author keywords

breast cancer; multigene assays; prognosis

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; KI 67 ANTIGEN; PACLITAXEL; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; BREAST CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL DECISION MAKING; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DNA MICROARRAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HIGH RISK PATIENT; HUMAN; PREDICTION; RECURRENCE FREE SURVIVAL; REVIEW; RISK ASSESSMENT; SCORING SYSTEM;

EID: 84886938806     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0033-1350831     Document Type: Review

References (89)

1. Goldhirsch A., Wood W. C., Coates A. S. et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol: 2011; 22 1736 1747
2. Peto R., Davies C., Godwin J. et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet: 2012; 379 432 444
3. Kreipe H. H., Ahrens P., Christgen M. et al. Jenseits von Staging, Typing und Grading. Herausforderungen und Perspektiven fur die Tumorpathologie der Mamma. Pathologe: 2010; 31 54 59
4. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature: 2012; 490 61 70
5. Weigelt B., Baehner F. L., Reis-Filho J. S. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol: 2010; 220 263 280
6. Lehmann B. D., Bauer J. A., Chen X. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest: 2011; 121 2750 2767
7. Perou C. M., Sorlie T., Eisen M. B. et al. Molecular portraits of human breast tumours. Nature: 2000; 406 747 752
8. Sorlie T., Perou C. M., Tibshirani R. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A: 2001; 98 10869 10874 (Pubitemid 32878711)
9. Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med: 2009; 360 790 800
10. Blows F. M., Driver K. E., Schmidt M. K. et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med: 2010; 7 e1000279
11. Bastien R. R., Rodriguez-Lescure A., Ebbert M. T. et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics: 2012; 5 44
12. Weigelt B., Horlings H. M., Kreike B. et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol: 2008; 216 141 150
13. Cheang M. C., Voduc K. D., Tu D. et al. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res: 2012; 18 2402 2412
14. Parker J. S., Mullins M., Cheang M. C. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol: 2009; 27 1160 1167
15. Reis P. P., Waldron L., Goswami R. S. et al. mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol: 2011; 11 46
16. Perou C. M., Parker J. S., Prat A. et al. Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol: 2010; 11 718 719 author reply 720-711
17. Chia S. K., Bramwell V. H., Tu D. et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res: 2012; 18 4465 4472
18. Kelly C. M., Bernard P. S., Krishnamurthy S. et al. Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX(R)) and the PAM50 breast cancer intrinsic Classifier in early-stage estrogen receptor-positive breast cancer. Oncologist: 2012; 17 492 498
19. Nguyen B., Cusumano P. G., Deck K. et al. Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients. Ann Surg Oncol: 2012; 19 3257 3263
20. Varga Z., Diebold J., Dommann-Scherrer C. et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS ONE: 2012; 7 e37379
21. Fountzilas G., Valavanis C., Kotoula V. et al. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med: 2012; 10 10
22. Noske A., Loibl S., Darb-Esfahani S. et al. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Res Treat: 2011; 126 109 117
23. Kim C., Tang G., Pogue-Geile K. L. et al. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J Clin Oncol: 2011; 29 4160 4167
24. Goldhirsch A., Ingle J., Gelber R. et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol: 2009; 20 1319 1329
25. Desmedt C., Haibe-Kains B., Wirapati P. et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res: 2008; 14 5158 5165
26. Wirapati P., Sotiriou C., Kunkel S. et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res: 2008; 10 R65
27. vant Veer L., Dai H., van de Vijver M. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature: 2002; 415 530 536 (Pubitemid 34130608)
28. Tian S., Roepman P., vant Veer L. J. et al. Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer. Biomark Insights: 2010; 5 129 138
29. van de Vijver M., He Y., vant Veer L. et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med: 2002; 347 1999 2009 (Pubitemid 35461656)
30. Buyse M., Loi S., vant Veer L. et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst: 2006; 98 1183 1192 (Pubitemid 44390989)
31. Bueno-de-Mesquita J. M., Linn S. C., Keijzer R. et al. Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat: 2009; 117 483 495
32. Wittner B. S., Sgroi D. C., Ryan P. D. et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res: 2008; 14 2988 2993
33. Mook S., Schmidt M. K., Viale G. et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat: 2009; 116 295 302
34. Mook S., Schmidt M. K., Weigelt B. et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol: 2010; 21 717 722
35. Knauer M., Mook S., Rutgers E. J. et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat: 2010; 120 655 661
36. Esteban J., Baker J., Cronin M. et al. Tumor Gene Expression and Prognosis in Breast Cancer: Multi-Gene RT-PCR Assay of Paraffin-embedded Tissue. Abstract #3416. Chicago, IL ASCO Annual Meeting: 2003
37. Cobleigh M. A., Bitterman P., Baker J. et al. Tumor Gene Expression predicts distant disease-free Survival (DDFS) in Breast Cancer Patients with 10 or more positive Nodes: high throughput RT-PCR Assay of Paraffin-embedded Tumor Tissues. Abstract #3466. Chicago, IL ASCO Annual Meeting: 2003
38. Paik S., Shak S., Tang G. et al. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients - NSABP studies B-20 and B-14. Breast Cancer Res Treat: 2003; 82 (Suppl.) S10 S11
39. Paik S., Shak S., Tang G. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med: 2004; 351 2817 2826 (Pubitemid 40051905)
40. Paik S., Tang G., Shak S. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol: 2006; 24 3726 3734 (Pubitemid 46622311)
41. Albain K. S., Barlow W. E., Shak S. et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol: 2010; 11 55 65
42. Sparano J. A., Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol: 2008; 26 721 728 (Pubitemid 351264384)
43. Markopoulos C. Overview of the use of Oncotype DX((R)) as an additional treatment decision tool in early breast cancer. Expert Rev Anticancer Ther: 2013; 13 179 194
44. Eiermann W., Rezai M., Kummel S. et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol: 2013; 24 618 624
45. Hornberger J., Chien R., Krebs K. et al. US insurance programs experience with a multigene assay for early-stage breast cancer. J Oncol Pract: 2011; 7 e38s e45s
46. Filipits M., Rudas M., Jakesz R. et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res: 2011; 17 6012 6020
47. Denkert C., Kronenwett R., Schlake W. et al. Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch: 2012; 460 251 259
48. Dubsky P. C., Jakesz R., Mlineritsch B. et al. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol: 2012; 30 722 728
49. Dubsky P., Filipits M., Jakesz R. et al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol: 2013; 24 640 647
50. Muller B. M., Keil E., Lehmann A. et al. The EndoPredict gene-expression assay in clinical practice - performance and impact on clinical decisions. PLoS ONE: 2013; 8 e68252
51. Nielsen T. O., Parker J. S., Leung S. et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res: 2010; 16 5222 5232
52. Dowsett M., Sestak I., Lopez-Knowles E. et al. Comparison of PAM50 risk of recurrence score with Oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol: 2013; 31 2783 2790
53. Martin M., Prat A., Rodriguez-Lescure A. et al. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat: 2013; 138 457 466
54. Rakha E. A., El-Sayed M. E., Lee A. H. et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol: 2008; 26 3153 3158
55. Rakha E. A., Reis-Filho J. S., Baehner F. et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res: 2010; 12 207
56. Paradiso A., Ellis I. O., Zito F. A. et al. Short- and long-term effects of a training session on pathologists performance: the INQAT experience for histological grading in breast cancer. J Clin Pathol: 2009; 62 279 281
57. Sotiriou C., Wirapati P., Loi S. et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst: 2006; 98 262 272 (Pubitemid 43264710)
58. Loi S., Haibe-Kains B., Desmedt C. et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol: 2007; 25 1239 1246 (Pubitemid 46640570)
59. Desmedt C., Giobbie-Hurder A., Neven P. et al. The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. BMC Med Genomics: 2009; 2 40
60. Naoi Y., Kishi K., Tanei T. et al. High genomic grade index associated with poor prognosis for lymph node-negative and estrogen receptor-positive breast cancers and with good response to chemotherapy. Cancer: 2011; 117 472 479
61. Liedtke C., Hatzis C., Symmans W. F. et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol: 2009; 27 3185 3191
62. Toussaint J., Sieuwerts A. M., Haibe-Kains B. et al. Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics: 2009; 10 424
63. Cuzick J., Dowsett M., Pineda S. et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol: 2011; 29 4273 4278
64. Barton S., Zabaglo L., AHern R. et al. Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. Br J Cancer: 2012; 106 1760 1765
65. Ring B. Z., Seitz R. S., Beck R. et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol: 2006; 24 3039 3047 (Pubitemid 46638938)
66. Ross D. T., Kim C. Y., Tang G. et al. Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials. Clin Cancer Res: 2008; 14 6602 6609
67. Bartlett J. M., Bloom K. J., Piper T. et al. Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. J Clin Oncol: 2012; 30 4477 4484
68. Weigelt B., Pusztai L., Ashworth A. et al. Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol: 2012; 9 58 64
69. Weigelt B., Reis-Filho J. S. Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry. Breast Cancer Res: 2010; 12 04 S5
70. Braun L., Mietzsch F., Seibold P. et al. Intrinsic breast cancer subtypes defined by estrogen receptor signalling-prognostic relevance of progesterone receptor loss. Mod Pathol: 2013; 10.1038/modpathol.2013.60
71. Elsawaf Z., Sinn H. P., Rom J. et al. Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour. Breast: 2013; 10.1016/j.breast.2013.05.012
72. Weigelt B., Reis-Filho J. S. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol: 2009; 6 718 730
73. Rakha E. A., Reis-Filho J. S., Ellis I. O. Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat: 2010; 120 293 308
74. Simon R. M., Paik S., Hayes D. F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst: 2009; 101 1446 1452
75. Fan C., Oh D. S., Wessels L. et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med: 2006; 355 560 569 (Pubitemid 44200649)
76. Varga Z., Sinn P., Fritzsche F. et al. Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer. PLoS ONE: 2013; 8 e58483
77. Prat A., Parker J. S., Fan C. et al. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol: 2012; 23 2866 2873
78. Robbins P., Pinder S., de Klerk N. et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol: 1995; 26 873 879
79. Gudlaugsson E., Skaland I., Janssen E. A. et al. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology: 2012; 61 1134 1144
80. Weigelt B., Mackay A., AHern R. et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol: 2010; 11 339 349
81. Geyer F. C., Marchio C., Reis-Filho J. S. The role of molecular analysis in breast cancer. Pathology: 2009; 41 77 88
82. Chang J. C., Makris A., Gutierrez M. C. et al. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat: 2008; 108 233 240 (Pubitemid 351311356)
83. Esteva F., Sahin A., Cristofanilli M. et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res: 2005; 11 3315 3319 (Pubitemid 40627881)
84. Denkert C., Loibl S., Kronenwett R. et al. RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy. Ann Oncol: 2013; 24 632 639
85. Symmans W. F., Hatzis C., Sotiriou C. et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol: 2010; 28 4111 4119
86. Bhargava R., Dabbs D. J. Oncotype DX test on unequivocally HER2-positive cases: potential for harm. J Clin Oncol: 2012; 30 570 571
87. Azim H. A. Jr., Michiels S., Zagouri F. et al. Utility of prognostic genomic tests in breast cancer practice: the IMPAKT 2012 Working Group consensus statement. Ann Oncol: 2013; 24 647 654
88. Scharl A. Mammakarzinom-Therapie: Der routinemäßige Einsatz von Gentests ist derzeit nicht sinnvoll. Dtsch Arztebl International: 2012; 109 2085 2086
89. Cardoso F., vant Veer L., Rutgers E. et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol: 2008; 26 729 735 (Pubitemid 351264385)